Jagsonpal Pharmaceuticals Ltd

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 11 September 2026, providing investors with the most up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a nuanced shift in its technical momentum, moving from a bullish to a mildly bullish stance as of early September 2026. Despite a slight dip in daily price, key indicators such as MACD and moving averages continue to support a cautiously optimistic outlook, while other metrics suggest a more tempered trend. This article analyses the recent technical developments and their implications for investors in the pharmaceuticals and biotechnology sector.

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics presented here reflect the stock's current position as of 31 August 2026, providing investors with the latest insights into the company’s performance and outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the company’s current position as of 20 August 2026, providing investors with an up-to-date view of its fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, with this rating last updated on 29 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 09 August 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has witnessed a notable shift in its technical momentum, with key indicators signalling a transition from a mildly bullish to a more confident bullish trend. Despite a recent day decline of 2.68%, the stock’s underlying technical parameters suggest improving momentum that could influence investor sentiment in the coming weeks.

Jagsonpal Pharmaceuticals Ltd. reported a robust first quarter for FY2027, with net profit surging 50.56% quarter-on-quarter to ₹13.19 crores, marking the company's strongest quarterly performance in recent history. The micro-cap pharmaceutical manufacturer, with a market capitalisation of ₹1,651.86 crores, saw its stock rally 8.70% following the results announcement, closing at ₹250.55 on July 30, 2026. However, despite the impressive operational performance, the company's valuation remains stretched at 34 times trailing earnings, raising questions about sustainability of current price levels.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 Jul 2026. However, the analysis and financial metrics discussed here reflect the stock’s current position as of 29 July 2026, providing investors with an up-to-date view of the company’s fundamentals, returns, and market performance.

Jagsonpal Pharmaceuticals Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 06 July 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 18 July 2026, providing investors with an up-to-date view of the company’s fundamentals, valuation, financial trends, and technical outlook.

Jagsonpal Pharmaceuticals Ltd has seen its investment rating downgraded from Hold to Sell, reflecting a combination of deteriorating financial trends, expensive valuation metrics, and a shift in technical indicators. Despite some long-term outperformance relative to the Sensex, recent quarterly results and technical signals have prompted a reassessment of the stock’s outlook.

Jagsonpal Pharmaceuticals Ltd has experienced a subtle shift in its technical momentum, moving from a bullish to a mildly bullish stance. Despite a modest day gain of 0.36%, the stock’s technical indicators present a nuanced picture, with some metrics signalling strength while others suggest caution. This article analyses the recent technical developments, placing them in the context of the company’s price performance and broader market trends.

Jagsonpal Pharmaceuticals Ltd is rated 'Hold' by MarketsMOJO, a rating that was last updated on 17 June 2026. While this rating change occurred on that date, the analysis and financial metrics discussed here reflect the company’s current position as of 29 June 2026, providing investors with the most up-to-date view of the stock’s fundamentals, returns, and market performance.

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Sell to Hold as of 17 June 2026, driven primarily by a marked improvement in technical indicators despite recent negative financial results. The company’s micro-cap status and mixed fundamental signals have led to a cautious stance, with the upgrade reflecting a nuanced balance between valuation, quality, financial trends, and technical momentum.

Jagsonpal Pharmaceuticals Ltd has experienced a notable shift in its technical momentum, moving from a mildly bullish stance to a more confident bullish trend on the weekly charts. Despite a recent day decline of 1.95%, the stock’s technical indicators reveal a complex interplay of signals that investors should carefully analyse before making decisions.

The 50-day moving average has crossed above the 200-day moving average for Jagsonpal Pharmaceuticals Ltd, signalling a golden cross on 15 Jun 2026. Yet, the broader technical and fundamental context presents a nuanced picture that calls for a closer look at the reliability of this signal.

Jagsonpal Pharmaceuticals Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 12 June 2026, driven primarily by a shift in technical indicators despite ongoing financial headwinds. The company’s Mojo Score rose to 42.0, reflecting a more positive technical outlook, although fundamental concerns remain. This article analyses the four key parameters—Quality, Valuation, Financial Trend, and Technicals—that influenced this rating change.